Bal Pharma Ltd

Stage 3 · Topping · week 2

As of 20 Nov 2026, Bal Pharma is in Stage 3, the topping phase, now in week 2 (since 13 Nov 2026). It closed at ₹83.21, 27.3% below its 52-week high and below its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. More about the company

₹83.2
Close, 20 Nov 2026
-1.65% on the day
₹132 Cr · Micro cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

BALPHARMA's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 69 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is BALPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 17w
S2 22w
S4 15w
S4 35w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 8w → S3 5w → S2 17w → S3 6w → S4 4w → S1 1w → S2 22w → S3 12w → S4 15w → S1 7w → S4 35w → S1 2w → S4 5w → S1 7w → S2 12w → S3 1w → S2 9w → S3 1w current
Total tracked: 168 weeks across 18 stage runs.

BALPHARMA among Pharmaceuticals61st of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…61BALPHARMAStage 3 · wk 269−4.7%
vs 52W High
-27.3%
₹60.4 lo₹114.5 hi
27.3% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 2
1w13w26w
Week 2, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-0.5%
200 DMA: ₹83.6 · rising
The stock has lost its 200-day average. In a topping stock that adds to the Stage 4 risk.
Rel Volume
0.08x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-4.7%
3M
-1.9%
6M
+4.2%
YTD
+13.5%
1Y
+4.1%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Scan Membership
Not in any scan now.
Last appeared 9 Sep 2026
Recent Stage Timeline
2026-11-20S3
Wk 2 · Vol 0.08x
2026-11-19S3
Wk 1 · Vol 0.15x
2026-11-18S3
Wk 1 · Vol 0.02x
2026-11-17S3
Wk 1 · Vol 0.14x
2026-11-16S3
Wk 1 · Vol 0.25x
2026-11-13S32→3
Wk 1 · Vol 0.31x
2026-11-12S2
Wk 9 · Vol 0.26x
2026-11-11S2
Wk 9 · Vol 0.17x
2026-11-09S2
Wk 9 · Vol 0.08x
2026-11-06S2
Wk 8 · Vol 0.17x
2026-11-05S2
Wk 8 · Vol 0.15x
2026-11-04S2
Wk 8 · Vol 0.18x
Moving averages & range
50 DMA
₹94.7
200 DMA
₹83.6
52W High
₹114.5
52W Low
₹60.4
5D Low
₹83.2
Resistance levels (recent highs)
20d High
₹90.9
60d High
₹114.5
120d High
₹114.5
250d High
₹114.5
Next resistance
+9.3%
to 20d High
P/E (TTM)
20.0
Forward —
Earnings Growth (YoY)
+446.2%
Revenue +34.5%
Dividend Yield
1.32%
P/B 1.8

Bal Pharma: quick answers

What stage is Bal Pharma in?

As of 20 Nov 2026, Bal Pharma (BALPHARMA) is in Stage 3, the topping phase. It entered Stage 3 on 13 Nov 2026 and is in week 2. What the four stages mean

Is Bal Pharma in an uptrend?

Its uptrend has stalled. Bal Pharma is in Stage 3, the topping phase that follows an advance. It trades 0.5% below its 200-day average, which is rising.

How far is Bal Pharma from its 52-week high?

Bal Pharma closed at ₹83.21 on 20 Nov 2026, 27.3% below its 52-week high of ₹114. Its 52-week low is ₹60.42.

How has Bal Pharma performed over the past year?

As of 20 Nov 2026, Bal Pharma is up 4.1% over the past year and up 13.5% so far in 2026.

Which sector and industry is Bal Pharma in?

Bal Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.